The patient's daughter-in-law
documents the improvements sustained through the first five months
of treatment with perispinal etanercept (PSE) in a patient with
severe dementia who flew to the INR from Hawaii for treatment.
Please see Perispinal etanercept for neuroinflammatory disorders. Edward
Tobinick MD. Drug Discovery Today 2009 Feb; 14(3-4):168-77.The
videos above are interviews discussing and documenting the clinical
response to initiation of anti-TNF treatment (perispinal etanercept)
at the INR. For the published results please see
Tobinick E, Gross H, Weinberger A, Cohen H., TNF-alpha Modulation
for Treatment of Alzheimer's Disease: A 6-Month Pilot Study
MedGenMed 2006; 8(2) :25; Tobinick E., Perispinal etanercept
for treatment of Alzheimer's disease, Current Alzheimer
Research 2007 Dec; 4(5):550-2; Tobinick E, Gross H., Rapid
improvement in verbal fluency and aphasia following perispinal
etanercept in Alzheimer's disease, BMC Neurology 2008;
8:27; and Tobinick E., Perispinal etanercept for neuroinflammatory
disorders, Drug Discovery Today 2009 Feb; 14(3-4):168-77.Institute for Neurological Research, a private medical group, inc.
100 UCLA Medical Plaza, Suites 205-210 Los Angeles, California
90095
Video2